| Ytd | -33.13% | |
| 1y | -81.60% |
| Open | 7.61 | Prev Close | 7.53 | Low | 7.53 | High | 7.77 | Mkt Cap | 8.85M |
| Vol | 10.36K | Avg Vol | 794.62K | EPS | -4.48 | P/E | -1.73 | Forward P/E | -0.29 |
| Beta | 1.41 | Short Ratio | 1.92 | Inst. Own | 0.51% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-22 | 50-d Avg | 11.24 | 200-d Avg | 11.53 | 1yr Est | 80.00 |
AKTX News
Discussion explores how combining complementary payload technologies may unlock new therapeutic oppo
Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report)'s stock price passed below its 200-day movin
Amazon reported strong Q2 results, beating revenue and earnings estimates. Shares jumped 11.9% in pr
Virtual Investor "What This Means" segment highlights strategic Whitehawk collaboration, acceleratin
Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-mark
TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tues
Globally recognized leader in early-phase oncology clinical development and experimental therapeutic
Consolidated closing of recently announced $5.5 million PIPE led by existing investors, combined wit
Discussion highlights growing importance on novel ADC payloads, and Akari's ASCO data in KRAS-driven
CEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagas
Discover why Akari Therapeutics PLC (NASDAQ: AKTX) stock is falling on Tuesday after last week's mas
Gainers: PHGE +97.3%, ARTL +74.8%, QTEX +52.4%, MNTX +34.4%, HLIT +28.3%, WOK +25%, CPSH +24.7%, COD
Akari Therapeutics Plc (NASDAQ:AKTX) shares are ripping higher after the company released preclinica
An ADC with a novel RNA spliceosome modulating payload PH1 paired with a KRAS inhibitor demonstrates
TAMPA, Fla. and LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an
Live webcast fireside chat with Abizer Gaslightwala, President and Chief Executive Officer, on Wedne
Patent reinforces strategic foundation for lead ADC AKTX-101 and expanding ADC pipeline to new molec
Patent covers proprietary 2nd generation Thailanstatin analog payload designed for use in ADCs (anti
Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report) saw a significant growth in short interest i
Expands potential opportunities for AKTX-101 and its novel RNA splicing modulator payload in additio
Superior potency demonstrated versus leading TROP2 ADCs across bladder, lung and breast tumor models
CEO Abizer Gaslightwala discusses the Company's strategic partnership with WuXi XDC and its implicat
Strategic Partnership Enables Akari to Accelerate IND Filing By Late 2026 Strategic Partnership Enab
